Open AccessClearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug
Author(s) -
Xuzhao Zhang,
Yun Liang,
Xian Li,
Weiqin Wang,
J Tong,
Yang Xu
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000022642
Subject(s) - medicine , bortezomib , hbsag , regimen , hepatitis b virus , entecavir , multiple myeloma , oncology , hepatitis b , gastroenterology , lamivudine , immunology , virus
Rationale: Reactivation of hepatitis B virus (HBV) after treatment with bortezomib-based regimens in HBV-positive patients with multiple myeloma (MM) has been reported in the past few years. Nevertheless, there is evidence of inhibition of HBV replication by bortezomib in transgenic mice. However, there is still no clinical evidence that bortezomib inhibits HBV. Patient concerns: A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs. Diagnoses: The diagnosis was MM with chronic carrier of HBV. Interventions: He received bortezomib-based regimen for MM as well as entecavir as a prophylaxis to prevent HBV reactivation. Outcomes: This patient achieved HBsAg and HBV-DNA clearance after 2 months and the remission was maintained during the next 2 years. He also achieved complete remission of MM and underwent consolidation therapy with autologous hematopoietic stem cell transplantation. Lessons: This is the first case of MM with HBV clearance after receiving a bortezomib-based regimen combined with anti-HBV drug. Research on related mechanisms might provide new suggestions and hope for better management of HBV positive patients with MM and for the treatment of HBV patients.